PMA device
Axsym Total Psa
Abbott Laboratories · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision May 20, 2011, newest Jun 10, 2011Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Axsym"
MAUDE reports
0
Brand "Axsym", since 2015
PubMed studies
543
Mentioning "Axsym"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Axsym Total Psa
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- AXSYM TOTAL PSAPMA supplement
P910007-S025 · Decided Jun 10, 2011 · 130 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- AXSYM TOTAL PSAPMA supplement
P910007-S022 · Decided May 20, 2011 · 200 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Axsym", any status and sponsor, newest update first.
No registered device study names "Axsym".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Axsym", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Axsym"[tiab]. The summary above synthesizes these.
- Total hCG tests.
Cole LA, DuToit S, Higgins TN · Clin Chim Acta · 2011
- [Personalized pharmacotherapy of digoxin].
Grundmann M, Kacíová I · Vnitr Lek · 2015
- Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies.
Azzazy HM, Chou PP, Tsushima JH, et al. · Ther Drug Monit · 1998Comparative Study, Multicenter Study
- Performance characteristics of the AxSYM D-dimer assay.
La'ulu SL, Dominguez CM, Roberts WL · Clin Chim Acta · 2008Research Support, Non-U.S. Gov't
- Performance characteristics of six homocysteine assays.
La'ulu SL, Rawlins ML, Pfeiffer CM, et al. · Am J Clin Pathol · 2008Comparative Study, Evaluation Study
- The association of thrombophilia in women with severe obstetric complications.
Alzahrani FM, Al-Mulhim A, Shaikh SS, et al. · J Med Life · 2022Meta-Analysis
- Evaluation of the AxSYM monoclonal cyclosporin assay and comparison with radioimmunoassay.
Sabaté I, Ginard M, González JM, et al. · Ther Drug Monit · 2000Comparative Study, Evaluation Study
- [Diagnostic utility of AxSYM anti-cyclic Citrullinated peptide antibody assay].
Kim KE, Kim KH, Woo KS, et al. · Korean J Lab Med · 2008Comparative Study, English Abstract
- Calibration of Abbott AxSYM Ferritin kit using the WHO Human Liver Ferritin International Standard 80/602.
Milman N, Juul-Jørgensen B, Bentzon MW · Eur J Clin Chem Clin Biochem · 1997Research Support, Non-U.S. Gov't
- Falsely elevated cardiac troponin I levels.
Makaryus AN, Makaryus MN, Hassid B · Clin Cardiol · 2007Case Reports
- Performance characteristics of the ARCHITECT Active-B12 (Holotranscobalamin) assay.
Merrigan SD, Owen WE, Straseski JA · Clin Lab · 2015Comparative Study, Research Support, Non-U.S. Gov't
- Comparison of the automated AxSYM and ADVIA centaur immunoassays for homocysteine determination.
Haltmayer M, Mueller T, Gegenhuber A, et al. · Clin Lab · 2004Comparative Study, Evaluation Study
Other devices of this type
Also filed under product code MTF.
- Elecsys total PSA, total PSA CalSet IIRoche Diagnostics Corp. · PMA 2023
- ARCHITECT Total PSA, Alinity i Total PSAAbbott Laboratories · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Atellica IM Total PSA II (tPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- Advia Centaur Psa AssaySiemens Healthcare Diagnostics · PMA 2017
- Abbott Architect Total PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation PsaSiemens Healthcare Diagnostics, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.